<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Innocan Pharma Corporation — News on 6ix</title>
<link>https://6ix.com/company/innocan-pharma-corporation</link>
<description>Latest news and press releases for Innocan Pharma Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 06 Apr 2026 10:52:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/innocan-pharma-corporation" rel="self" type="application/rss+xml" />
<item>
<title>Innocan Pharma Announces Closing of Additional Debenture</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-closing-of-additional-debenture</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-closing-of-additional-debenture</guid>
<pubDate>Mon, 06 Apr 2026 10:52:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced offering of an additional debenture of the Company (the "Debenture") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $200,000 (the "Offering"). This follows the completion of the offering to Tamar Innovest of a debenture in the principal amount of $450,000 on March 11, 2026.</description>
</item>
<item>
<title>Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-offering-of-an-additional-debenture-to-tamar-innovest</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-offering-of-an-additional-debenture-to-tamar-innovest</guid>
<pubDate>Tue, 31 Mar 2026 14:20:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture of the Company (the "Debenture") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $200,000 (the "Offering"). This follows the completion of the offering to Tamar Innovest of a debenture in the principal amount of US $450,000 (the "Prior Debenture") to Tamar Innovest on March 11, 2026.</description>
</item>
<item>
<title>Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-reports-2025-financial-results-with-revenues-at-us-dollar266m</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-reports-2025-financial-results-with-revenues-at-us-dollar266m</guid>
<pubDate>Tue, 31 Mar 2026 07:00:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its audited financial consolidated results for the year ended December 31, 2025.</description>
</item>
<item>
<title>Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-closing-of-a-debenture-to-its-largest-shareholder-tamar-innovest</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-closing-of-a-debenture-to-its-largest-shareholder-tamar-innovest</guid>
<pubDate>Mon, 16 Mar 2026 21:03:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced offering of a debenture of the Company (the "Debenture") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $450,000 (the "Offering").</description>
</item>
<item>
<title>Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-offering-of-a-debenture-to-its-largest-shareholder-tamar-innovest</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-offering-of-a-debenture-to-its-largest-shareholder-tamar-innovest</guid>
<pubDate>Wed, 11 Mar 2026 22:42:00 GMT</pubDate>
<description>Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest ...</description>
</item>
<item>
<title>FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/fda-center-for-veterinary-medicine-grants-innocan-a-fee-waiver-in-2026-for-the-third-consecutive-time</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/fda-center-for-veterinary-medicine-grants-innocan-a-fee-waiver-in-2026-for-the-third-consecutive-time</guid>
<pubDate>Fri, 27 Feb 2026 21:30:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year.</description>
</item>
<item>
<title>Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-lpt-cbd-140700479</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-lpt-cbd-140700479</guid>
<pubDate>Mon, 09 Feb 2026 14:07:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial" in the esteemed peer reviewed journal Frontiers in veterinary science (https://doi.org/10.3389/fvets.20</description>
</item>
<item>
<title>Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-corporation-anticipates-listing-210000915</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-corporation-anticipates-listing-210000915</guid>
<pubDate>Tue, 27 Jan 2026 21:00:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, today announced that, further to its press release dated January 2, 2026, it now anticipates to list on NYSE American on or around January 30, 2026, subject to approval of its listing application and continued compliance with exchange rules." subject to authorization of the application and continu</description>
</item>
<item>
<title>Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-public-filing-154000445</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-public-filing-154000445</guid>
<pubDate>Wed, 10 Dec 2025 15:40:00 GMT</pubDate>
<description>Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that, further to its press release of July 23, 2025, it has publicly filed an amendment to its registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed public offering of units (each, a "Unit" and collectively, the "Units") in the United States. The original registration statement was filed on July 23, 2025.</description>
</item>
<item>
<title>Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-reports-financial-results-063400643</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-reports-financial-results-063400643</guid>
<pubDate>Thu, 27 Nov 2025 06:34:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its financial consolidated results for the nine months ended September 30, 2025 and provide a Company update.</description>
</item>
<item>
<title>Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-promising-translational-210100947</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-promising-translational-210100947</guid>
<pubDate>Mon, 24 Nov 2025 21:01:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats" in the peer reviewed esteemed journal Frontiers in Pharmacology (https://doi.org/10.3389/fphar.2025.168922</description>
</item>
<item>
<title>Innocan Pharma announces promising results of LPT-CBD administered to Gottingen Minipigs, a well-known drug toxicology model</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-promising-results-210100360</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-promising-results-210100360</guid>
<pubDate>Thu, 20 Nov 2025 21:01:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Liposomal-Cannabidiol Injection: Preliminary Insights into Pharmacokinetics and Safety Characteristics in Göttingen Minipigs and Rabbits" in the esteemed journal Precision Nanomedicine (https://doi.org/10.33218/001c.141764.) (1).</description>
</item>
<item>
<title>Innocan Pharma to Present at the 2025 ThinkEquity Conference</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-present-2025-thinkequity-200100407</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-present-2025-thinkequity-200100407</guid>
<pubDate>Fri, 24 Oct 2025 20:01:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it will be participating in The ThinkEquity Conference, taking place October 30, 2025, at the Mandarin Oriental, New York City.</description>
</item>
<item>
<title>Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/liposomal-cbd-injection-technology-lpt-200000578</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/liposomal-cbd-injection-technology-lpt-200000578</guid>
<pubDate>Wed, 15 Oct 2025 20:00:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its patent for LPT-CBD was allowed in Japan and will be officially granted upon completion of the administrative process. The patent covers a prolonged-release liposome-based formulation that encapsulates cannabinoids.</description>
</item>
<item>
<title>Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-partners-sanctuary-injured-200000222</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-partners-sanctuary-injured-200000222</guid>
<pubDate>Thu, 18 Sep 2025 20:00:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce its ongoing collaboration with Freedom Farm, a sanctuary dedicated to rescuing animals that were expelled from the industrial farms as a result of the animals having physical disabilities and other medical conditions. Through this collaboration, Freedom Farm animals that suffer from painful conditions receive compassio</description>
</item>
<item>
<title>Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharmas-poster-liposomal-synthetic-200100167</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharmas-poster-liposomal-synthetic-200100167</guid>
<pubDate>Mon, 15 Sep 2025 20:01:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its LPT-CBD poster presentation, delivered by Dr. Joseph V. Pergolizzi, Jr., MD, MBA, at the PAINWeek conference in Las Vegas, sparked genuine enthusiasm among conference participants.</description>
</item>
<item>
<title>Innocan Pharma Announces Details of Proposed Share Consolidation</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-details-proposed-200000776</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-details-proposed-200000776</guid>
<pubDate>Fri, 29 Aug 2025 20:00:00 GMT</pubDate>
<description>Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that further to its press release dated July 23, 2025, it will be consolidating all of its issued and outstanding common shares ("Common Shares") on the basis of one (1) post-consolidation Common Share for each 65 pre-consolidation Common Shares (the "Share Consolidation"). The Share Consolidation represents another step towards the completion of a proposed public offering of unit</description>
</item>
<item>
<title>Innocan Pharma Announces First Half Of 2025 Financial Results</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-first-half-200100659</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-first-half-200100659</guid>
<pubDate>Wed, 27 Aug 2025 20:01:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its financial consolidated results for the six months ended June 30, 2025. This period delivered a positive swing in Innocan's operating profitability together with continued strengthening of its balance sheet.</description>
</item>
<item>
<title>Innocan's Findings to be Showcased in Scientific Poster Reception at PAINWeek 2025 Conference in Las Vegas, Nevada</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocans-findings-showcased-scientific-poster-200000047</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocans-findings-showcased-scientific-poster-200000047</guid>
<pubDate>Fri, 22 Aug 2025 20:00:00 GMT</pubDate>
<description>Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that during the PAINWeek conference 2025, it will showcase a poster outlining key data on LPT-CBD pharmacokinetics and efficacy along with the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: https://doi.org/10.7759/cureus.81577). PAINWeek</description>
</item>
<item>
<title>Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering</title>
<link>https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-public-filing-214700399</link>
<guid isPermaLink="true">https://6ix.com/company/innocan-pharma-corporation/news/innocan-pharma-announces-public-filing-214700399</guid>
<pubDate>Wed, 23 Jul 2025 21:47:00 GMT</pubDate>
<description>Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed public offering of units (each, a "Unit" and collectively, the "Units") in the United States.</description>
</item>
</channel>
</rss>